1-6 of 6
Ke-Da Yu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial

Li Chen, Yi-Zhou Jiang, Song-Yang Wu, Jiong Wu, Gen-Hong Di, Guang-Yu Liu, Ke-Da Yu, Lei Fan, Jun-Jie Li, Yi-Feng Hou, Zhen Hu, Can-Ming Chen, Xiao-Yan Huang, A-Yong Cao, Xin Hu, Shen Zhao, Xiao-Yan Ma, Ying Xu, Xiang-Jie Sun, Wen-Jun Chai, Xiaomao Guo, Xizi Chen, Yanhui Xu, Xiao-Yu Zhu, Jian-Jun Zou, Wen-Tao Yang, Zhong-Hua Wang, Zhi-Ming Shao
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (13): 2807–2817.
https://doi.org/10.1158/1078-0432.CCR-21-4313
Published: 01 July 2022
View article titled, Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Open the PDF for Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial in another window
Includes: Supplementary data
Journal Articles

Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer

Yi Xiao, Ding Ma, Shen Zhao, Chen Suo, Jinxiu Shi, Meng-Zhu Xue, Miao Ruan, Hai Wang, Jingjing Zhao, Qin Li, Peng Wang, Leming Shi, Wen-Tao Yang, Wei Huang, Xin Hu, Ke-Da Yu, Shenglin Huang, François Bertucci, Yi-Zhou Jiang, Zhi-Ming Shao
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (16): 5002–5014.
https://doi.org/10.1158/1078-0432.CCR-18-3524
Published: 15 August 2019
View article titled, Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer
Open the PDF for Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer

Wen-Jia Zuo, Yi-Zhou Jiang, Yu-Jie Wang, Xiao-En Xu, Xin Hu, Guang-Yu Liu, Jiong Wu, Gen-Hong Di, Ke-Da Yu, Zhi-Ming Shao
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (19): 4859–4869.
https://doi.org/10.1158/1078-0432.CCR-15-3036
Published: 02 October 2016
View article titled, Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer
Open the PDF for Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer

Yi-Rong Liu, Yi-Zhou Jiang, Xiao-En Xu, Xin Hu, Ke-Da Yu, Zhi-Ming Shao
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (7): 1653–1662.
https://doi.org/10.1158/1078-0432.CCR-15-1555
Published: 31 March 2016
View article titled, Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer
Open the PDF for Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

The Residual Tumor Autophagy Marker LC3B Serves as a Prognostic Marker in Local Advanced Breast Cancer after Neoadjuvant Chemotherapy

Sheng Chen, Yi-Zhou Jiang, Liang Huang, Ruo-Ji Zhou, Ke-Da Yu, Yin Liu, Zhi-Ming Shao
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (24): 6853–6862.
https://doi.org/10.1158/1078-0432.CCR-13-1617
Published: 16 December 2013
View article titled, The Residual Tumor Autophagy Marker LC3B Serves as a Prognostic Marker in Local Advanced Breast Cancer after Neoadjuvant Chemotherapy
Open the PDF for The Residual Tumor Autophagy Marker LC3B Serves as a Prognostic Marker in Local Advanced Breast Cancer after Neoadjuvant Chemotherapy in another window
Journal Articles

Identification of Prognosis-Relevant Subgroups in Patients with Chemoresistant Triple-Negative Breast Cancer

Ke-Da Yu, Rui Zhu, Ming Zhan, Angel A. Rodriguez, Wei Yang, Stephen Wong, Andreas Makris, Brian D. Lehmann, Xi Chen, Ingrid Mayer, Jennifer A. Pietenpol, Zhi-Ming Shao, W. Fraser Symmans, Jenny C. Chang
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (10): 2723–2733.
https://doi.org/10.1158/1078-0432.CCR-12-2986
Published: 12 May 2013
View article titled, Identification of Prognosis-Relevant Subgroups in Patients with Chemoresistant Triple-Negative Breast Cancer
Open the PDF for Identification of Prognosis-Relevant Subgroups in Patients with Chemoresistant Triple-Negative Breast Cancer in another window
Includes: Supplementary data